Prot# TAS108-0004: Phz 2, Rndmzd, Dbl-Bld E&S Study of 3 Doses of TAS-108 Admin'd Orally in Postmenopausal Patients w/ Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard 1st Line Endocrine Therap

Project: Research project

Project Details

Effective start/end date6/25/042/12/10


  • Quintiles, Inc. (TAS108-0004 // TAS108-0004)
  • Taiho Pharmaceutical Co., Ltd. (TAS108-0004 // TAS108-0004)